Evidence map›Paper›PMID 40757929›Full record

ArticleCornea2025

Adjunctive Topical Calcineurin Inhibitors During the Treatment of Fungal Keratitis: Practice Patterns and Opinions.

Josephine Christy, Vishwanath Prathikanti, Sarah Abdelrahmen, Douglas Pula, Jennifer Rose-Nussbaumer, N Venkatesh Prajna, Thomas M Lietman, Gerami D Seitzman

Abstract read
In one paragraph

Article in Cornea, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Emerging treatments in fungal keratitis.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
  2. Anti-inflammatory treatments in microbial keratitis.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Josephine ChristyAravind Eye Hospital, Pondicherry, India.
Vishwanath PrathikantiFrancis I. Proctor Foundation, University of California, San Francisco, CA.
Sarah AbdelrahmenFrancis I. Proctor Foundation, University of California, San Francisco, CA.
Douglas PulaFrancis I. Proctor Foundation, University of California, San Francisco, CA.
Jennifer Rose-NussbaumerDepartment of Ophthalmology, Stanford University, Palo Alto, CA.
N Venkatesh PrajnaAravind Eye Hospital, Madurai, India; and.
Thomas M LietmanFrancis I. Proctor Foundation, University of California, San Francisco, CA.
Gerami D SeitzmanFrancis I. Proctor Foundation, University of California, San Francisco, CA.ORCID 0000-0003-1791-5509

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAMBA, DEEPAK ASHOK · 1985 to 2024
$16.8M
UCSF-Proctor Clinician Vision Scholars K12 ProgramK12EY031372 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMAS M LIETMAN, Yvonne Ou · 2020 to 2026
$3.9M
Vision Bioinformatics and ComputationP30EY037668 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Erik M Ullian · 2025 to 2026
$2.0M
NEI NIH HHS EY002162NEI NIH HHS K12 EY031372NEI NIH HHS K12EY031372NEI NIH HHS P30 EY002162NEI NIH HHS P30 EY037668
6 · The paper itself

Abstract

purposeSuccessful antifungal treatment for fungal keratitis does not always result in a good visual outcome. Both infectious and inflammatory components of the disease result in visually significant corneal opacification. We conducted a survey of cornea specialists to elicit expert opinion on the role topical calcineurin inhibitors may play in the management of fungal keratitis.

methodsAn online survey was sent to subscribers of several cornea-focused listservs. Descriptive statistics were performed.

resultsOne hundred thirty-five participants completed the online survey. Approximately 48% of respondents practiced medicine in the United States and 36% in India. About 23% presently "sometimes" prescribe topical calcineurin inhibitors. And 70% never prescribe. When administered adjunctively to topical antifungal drops, 59% of respondents predict 1% to 2% topical cyclosporin would have a clinically significant antiinflammatory effect compared with 33% for the 0.05% to 0.1% cyclosporin dose. About 50% believe the 0.1% tacrolimus dose would have a clinically significant antiinflammatory activity compared with the 0.03% tacrolimus dose. Overall, those surveyed predicted adjunctive topical calcineurin inhibitors could improve final visual acuity by almost one line of vision.

conclusionsVaried opinions exist regarding the role adjunctive topical calcineurin inhibitors can play during a treatment course of fungal keratitis. The overall impression is that these agents may help clinical outcome.

Indexed as

Antifungal AgentsCalcineurin InhibitorsCorneal UlcerEye Infections, FungalImmunosuppressive AgentsKeratitisPractice Patterns, Physicians'Administration, TopicalCyclosporineDrug Therapy, CombinationHumansOphthalmic SolutionsSurveys and QuestionnairesTacrolimusVisual AcuityAntifungal AgentsCalcineurin InhibitorsCyclosporineImmunosuppressive AgentsOphthalmic SolutionsTacrolimuscalcineurin inhibitorscyclosporinefungal keratitistacrolimus

Identifiers

PMID40757929
PMCPMC13158013

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.